Filing identity and reporting period
Important discrepancy: The supplied filing is Venaxis, Inc.’s Form 10-Q for the quarter ended June 30, 2016—not a filing by Riot Platforms, Inc. Confirm the issuer and filing before relying on this summary.
The filing covers the three and six months ended June 30, 2016, with comparisons to 2015. Financial statements are unaudited. Amounts below are in U.S. dollars.
Financial performance and liquidity
| Metric | Q2 2016 | First six months 2016 | Comparable 2015 period |
|---|---|---|---|
| Product sales | $0 | $0 | $24,517 Q2; $35,805 six months |
| License-fee revenue | $24,174 | $48,349 | Same amounts |
| Operating loss | $(871,746) | $(2,250,283) | $(1,994,421) Q2; $(4,206,558) six months |
| Net loss | $(835,875) | $(276,364) | $(2,033,235) Q2; $(4,219,608) six months |
| Net loss per share | $(0.22) | $(0.07) | $(0.52) Q2; $(1.09) six months |
| Operating cash flow | Not separately presented | $(2,546,076) | $(3,825,014) six months |
Six-month 2016 net loss was substantially reduced by a $1.92 million gain on the sale of the company headquarters; the six-month operating loss was $2.25 million. The company reported $16.15 million of cash, cash equivalents and short-term investments, $15.80 million of working capital, total assets of $17.59 million, and stockholders’ equity of $16.02 million at June 30. Total liabilities were $1.57 million, including deferred revenue; the company reported no debt at quarter-end. No product-sales gross profit was recorded in 2016. The filing does not provide a meaningful operating margin for this period.
Material changes versus the prior period
- Product sales stopped: the company recorded no sales in the first half of 2016, versus $35,805 in the first half of 2015, following the APPY 1 commercial wind-down.
- Operating expenses declined: first-half selling, general and administrative expense fell 39% to $1.85 million, and research and development expense fell 65% to $446,000, mainly due to reduced commercialization, development and staffing activity.
- The headquarters sale generated approximately $1.7 million of net cash after expenses and mortgage payoffs and a reported gain of approximately $1.9 million. The company continued to lease back needed space.
- Interest expense decreased after the mortgage was repaid. Investment income was $79,392 for the first half, compared with $36,209 in 2015.
- A one-for-eight reverse stock split took effect March 31, 2016; share and per-share figures in the filing reflect the split.
Outlook, risks and unusual items
- Management expected near-term operating losses, potentially significant, but believed available working capital would fund estimated needs into 2017. The company said it was monitoring cash and expenses and might seek additional financing; it gave no assurance financing would be available on acceptable terms.
- The proposed Strand Life Sciences combination was terminated by mutual agreement on March 11, 2016. Venaxis was evaluating strategic alternatives, including partnering, licensing or monetizing its appendicitis assets and continued cost controls. No transaction or formal financial guidance was disclosed.
- Management warned that approximately $371,000 of capitalized acute-appendicitis patent costs could be impaired if it could not find a strategic partner or other party to advance the portfolio. The filing also reports $168,000 of patent impairment charges for the first half.
- Venaxis had wound down APPY 1 activity after limited sales and losses; the FDA had previously determined that the APPY1 Test did not meet criteria for clearance as a class II medical device. Two European distributors disputed termination of their agreements. Management considered their claims without merit and did not expect a material financial impact; the parties were attempting to resolve the dispute without arbitration.
- The company disclosed recurring operating losses and negative operating cash flows. Management stated that the financial statements did not include adjustments that might be required if the company could not continue as a going concern.
- Ceva’s animal-health license continued to produce amortized license revenue. Potential future milestones and royalties depend on achievement of specified milestones and product sales; they are not assured revenue.
Key facts investors should verify
- Confirm whether this Venaxis filing is the intended document, given the Riot Platforms metadata.
- Review the company’s cash consumption, investment liquidity and stated runway into 2017, including any subsequent financing or spending changes.
- Check the status and recoverability of the appendicitis patents and other development assets, and whether a partner or strategic transaction was secured.
- Verify the resolution of the European distributor dispute and any resulting costs or liabilities.
- Assess whether reported earnings comparisons are distorted by the one-time headquarters-sale gain and the absence of product sales.